SPG Block for Acute Pediatric Migraine
SPG Block for Acute Pediatric Migraine
This is a randomized double blind trial comparing an intranasal sphenopalatine block with 2%
 lidocaine to intravenous (0.15 mg/kg, max 10mg) prochlorperazine in patients greater than 10
 years of age presenting to a pediatric emergency department with an acute frontal migraine
 headache.
This is a randomized double blind trial comparing an intranasal sphenopalatine block with 2%
 lidocaine to intravenous (0.15 mg/kg, max 10mg) prochlorperazine in patients greater than 10
 years of age presenting to a pediatric emergency department with an acute frontal migraine
 headache. Excluded populations include those with sickle cell, concern for CNS infection
Inclusion Criteria:

 - Frontal migraine headache

 Exclusion Criteria:

 -  Non-english speaking

 -  Known pregnancy

 -  Sickle cell hemaglobinopathy

 -  Concern for CNS infection

 -  Acute febrile illness

 -  non-frontal headaches

 -  Concern for increased intracranial pressure